摘要
目的:探索一次性制备基因修饰自体造血干细胞产品的可能性.方法:将β-地中海贫血患者来源的造血干细胞分为五组, Con组: X-VIVO 20完全培养基;组1: SR-1 + X-VIVO 20完全培养基;组2: UM171 +X-VIVO 20完全培养基;组3: SR-1 +UM171 + X-VIVO 20完全培养基,组4为分选后冻存的CD34+细胞.观察不同的细胞因子或组合对长期培养中CD34+细胞增殖能力、干性维持等的变化.结果:在84小时培养时,组3的CD34+细胞百分比最高,达(89.8±4.8)%,细胞数目为(4.13±0.61)×10^6, CFU检测示其集落形成能力(177.7±5.5)与组4 (178.3±9.5)无统计学差异,小鼠植入试验表明组3和组4在3个月和6个月时,植入能力无统计学差异.超过84小时,无论采用何种方法培养CD34+细胞,其CD34+百分比及集落形成能力均逐渐下降.结论: SR-1、 UM171、 UM171+SR1等细胞因子或组合,均能在造血干细胞增殖的同时,维持干性. 84小时培养, UM171+SR1对于造血干细胞的干性维持效果最佳,也能较好地促进增殖,适合用于基因治疗的细胞培养.
Objective: To explore the possibility of one-step production of genetically modified autologous hematopoietic stem cells. Methods: The hematopoietic stem cells from beta thalassemia patients were divided into five groups: Con group (X-VIVO 20 complete medium), Group 1(SR-1 plus X-VIVO 20 complete medium), Group 2 (UM171 plus X-VIVO 20 complete medium), Group 3 (SR-1 plus UM171 and X-VIVO 20 complete medium), Group 4 (Cryopreserved CD34+cells after separation). The cell number, phenotype and colony formation ability were compared among different?groups. Results: In 84 hours, the percentage of CD34+cells in group 3 was the highest (89.8 ± 4.8)%, and the number of cells was (4.13±0.61)×10^6. There was no significant difference between group 3 and group 4 on colony formation ability (177.7±5.5 vs 178.3±9.5) and chimerism rate in NSI mice on third and sixth month. The phenotype and colony formation ability of each cultured group declined after 84 hours. Conclusion: Either cytokines or combination can maintain stemness of CD34^+cells from beta thalassemia patients and promote these cells proliferation. Group 3 (SR-1 plus UM171 and X-VIVO 20 complete medium) is the best option to maintain stemness of CD34^+cells and promote proliferation in 84 hours. This method can be applied for gene therapy.
作者
罗昀
邢晓
郭栋
莫瑞麟
郭伟
LUO Yun;XING Xiao;GUO Dong(Guangdong YiKe Gene and Cellular Therapeutics Tech Co.,Ltd, Guangdong Dongguan 523808)
出处
《医学检验与临床》
2018年第12期22-26,16,共6页
Medical Laboratory Science and Clinics